Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novartis Pharmaceuticals
Age
40–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male or female adults aged ≥40 years
Patients with moderate to severe COPD defined by a post-bronchodilator Forced Expiratory Volume in One Second (FEV1)/(FVC) Forced Vital Capacity ratio of \<0.70 and a post-bronchodilator FEV1 of ≤70% and FEV1 ≥ 30% of predicted normal values.
Current or ex-smokers who have a smoking history of at least 10 pack years.
You may not be if
Pregnant or nursing (lactating) women
Patients who have a clinically significant laboratory abnormality at run-in
Patients with narrow-angle glaucoma, symptomatic benign prostatic hyperplasia or bladder-neck obstruction or moderate to severe renal impairment (GFR \<50 ml/min/1,732) or urinary retention. (BPH patients who are stable on treatment can be considered).
Patients with any history of asthma
Patients with pulmonary lobectomy or lung volume reduction surgery or lung transplantation
Patients receiving medications in the classes listed in the protocol as prohibited.
Clareo Health | Efficacy of NVA237 Compared to Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD)
